# US 2026/0028608 A1 · Cysteine protease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0028608 A1
- Document ID: US20260028608A1
- Status: Published application
- Kind: A1
- Application number: 19/354,148
- Filed: 2025-10-09
- Published: 2026-01-29
- Earliest claimed: 2020-05-19
- Assignees: Hansa Biopharma AB
- Applicants: Hansa Biopharma AB
- Inventors: Emma Andersson Nordahl; Christian Kjellman; Kaisa Karhumaa; Karl Markus Roupé; Robert Bockermann; Sofia Järnum
- Web page: https://patentgrep.com/patent/US20260028608A1

## CPC

- C12N 9/52: derived from bacteria {or Archaea}
- C12N 15/70: Vectors or expression systems specially adapted for E. coli
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/21: containing a His-tag
- C12Y 304/22: Cysteine endopeptidases (3.4.22)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

The present invention relates to a novel polypeptide which displays IgG cysteine protease activity, and in vivo and ex vivo uses thereof. Uses of the polypeptide include methods for the prevention or treatment of diseases and conditions mediated by IgG, and methods for the analysis of IgG and in vitro generation of F(ab′)2 fragments.

## Claims

### Claim 1

A polypeptide having IgG cysteine protease activity and comprising or consisting of an amino acid sequence which is:
(i) SEQ ID NO: 1; or
(ii) SEQ ID NO: 2; or
(iii) a variant of SEQ ID NO: 1 or SEQ ID NO: 2, which has 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modification(s) relative to SEQ ID NO: 1 or SEQ ID NO: 2 respectively, provided that the sequence retains: (a) an asparagine (N) at the position which corresponds to position 95 of SEQ ID NO: 5, (b) an aspartic acid (D) at the position which corresponds to position 99 of SEQ ID NO: 5 and (c) an asparagine (N) at the position which corresponds to position 226 of SEQ ID NO: 5, and provided that the polypeptide is at least as effective at cleaving human IgG as the polypeptide consisting of the amino acid sequence of SEQ ID NOs: 1 or 2 respectively, when measured in the same assay.

### Claim 2 (depends on 1)

The polypeptide according to claim 1, wherein at least one of the modifications in (iii) does not result in the same amino acid as is present in the corresponding position in the polypeptide sequence of SEQ ID NO: 3, preferably wherein all of the modifications in (iii) do not result in the same amino acid as is present in the corresponding position in the polypeptide sequence of SEQ ID NO: 3.

### Claim 3 (depends on 1)

A polypeptide according to claim 1, wherein the polypeptide further comprises an additional methionine at the N terminus and/or an additional histidine tag at the C terminus.

### Claim 4 (depends on 1)

A polypeptide according to claim 1, wherein the polypeptide is more effective at cleaving human IgG than an IdeZ polypeptide and/or is at least as effective at cleaving human IgG as an IdeS polypeptide, when measured in the same assay.

### Claim 5 (depends on 1)

A polypeptide according to claim 1, wherein the polypeptide is more effective at cleaving human IgG than an IdeS polypeptide when measured in the same assay, optionally wherein efficacy is measured in vitro in a blood or serum sample taken from a human subject.

### Claim 6 (depends on 5)

A polypeptide according to claim 5, wherein the polypeptide is at least 1.2 fold, preferably 1.3 fold, most preferably 1.4 fold more effective at cleaving human IgG than an IdeS polypeptide when measured in the same assay.

### Claim 7 (depends on 1)

A polypeptide according to claim 1, wherein said polypeptide is less immunogenic than an IdeS polypeptide and/or is not more immunogenic than an IdeZ polypeptide, when measured in the same assay.

### Claim 8 (depends on 1)

A polypeptide according to claim 1, wherein the polypeptide is less immunogenic than an IdeS polypeptide, preferably wherein the immunogenicity of the polypeptide is no more than 85% of the immunogenicity of an IdeS polypeptide when measured in the same assay.

### Claim 9 (depends on 1)

A polynucleotide or expression vector which comprises a nucleic acid sequence encoding a polypeptide according to claim 1 or a composition comprising a polypeptide according to claim 1 and at least one pharmaceutically acceptable carrier or diluent.

### Claim 10 (depends on 9)

A host cell comprising the polynucleotide or expression vector according to claim 9, which is preferably a bacterial cell, most preferably a cell of E. coli.

### Claim 11 (depends on 1, 9)

A method for:
a) the prevention or treatment of a disease or condition in a subject, which method comprises administering a polypeptide according to claim 1 or the composition of claim 9 to the subject in a prophylactically or therapeutically effective amount; or
b) the cleavage of IgG which is carried out ex vivo, the method comprising contacting a sample containing IgG with a polypeptide according to claim 1 under conditions which permit IgG cysteine protease activity to occur.

### Claim 12 (depends on 11)

A method according to claim 11a, wherein said disease or condition is a disease or condition mediated in whole or in part by pathogenic IgG antibodies, preferably wherein said disease or condition is listed in Table D.

### Claim 13 (depends on 11)

A method according to claim 11b which is conducted to generate Fc, Fab and/or F(ab′)2 fragments.

### Claim 14 (depends on 12)

A method according to claim 12 wherein the sample is a blood sample taken from a subject suffering from a disease or condition as defined in claim 12.
